Demonstrated Safety Profile

Combined adverse reactions (ARs) in ≥10% of patients with MCL (N=118)1

Adverse reactions All Grades (%) Grade ≥3 (%)
Upper respiratory tract infection 39 0
Neutropenia and Neutrophil count decreased 38 15
Rash 36 0
Thrombocytopenia and Platelet count decreased 27 5
Leukopenia and White blood count decreased 25 5
Diarrhea 23 0.8
Pneumonia 15 10
Anemia and Hemoglobin decreased 14 8
Musculoskeletal pain 14 3.4
Hypokalemia 14 1.7
Bruising 14 0
Constipation 13 0
Hypertension 12 3.4
Cough 12 0
Hemorrhage 11 3.4
Urinary tract infection 11 0.8

The most common ARs (≥ 20%; pooled safety population N=629), included neutrophil count decreased (53%), platelet count decreased (39%), upper respiratory tract infection (38%), white blood cell count decreased (30%), hemoglobin decreased (29%), rash (25%), bruising (23%), diarrhea (20%), and cough (20%).




Combined incidence of cardiac arrhythmias in patients with hematologic malignancies (N=629)1

Adverse reaction All Grades (%) Grade ≥3 (%)
Atrial fibrillation and atrial flutter 2.0 0.6

Combined dose reduction and discontinuation rates1

Median duration of treatment: 17.5 months (range: 0.2-33.9 months)2

Dose reductions due to ARs
0.8%
(1/118) of patients
Discontinuation
rate
due to ARs
7%
(8/118) of patients

Powerful And
Sustained Responses

Efficacy

Flexible
Dosing

Dosing
myBeiGene

Personalized Patient
Support Program

Patient Support